Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Xenon said the awards to eight employees and Alpha Cognition’s grant to one employee were approved as hiring inducements under Nasdaq rules.
- On October 1, 2026, Xenon Pharmaceuticals Inc., Alpha Cognition Inc., and Taysha Gene Therapies, Inc. announced equity inducement grants to new employees under Nasdaq Listing Rule 5635.
- Compensation committees at each firm approved the awards as material inducements to attract new hires, complying with Nasdaq rules permitting equity grants for employment incentives.
- Xenon granted eight new non-officer employees 17,850 share options and 10,500 restricted share units, with vesting tied to continued service.
- Taysha Gene Therapies issued 384,000 restricted share units and 92,400 share options to four employees; Alpha Cognition Inc. granted 6,000 options to one new hire.
- These biopharmaceutical firms are advancing clinical-stage research for epilepsy, Alzheimer's disease, and Rett syndrome, strengthening teams to support drug development and commercialization.
15 Articles
15 Articles
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants…
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today…
Coverage Details
Bias Distribution
- 55% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
















